In that phase I/II study, 10 EOC patients with minimal residual disease after initial debulking and chemotherapy were treated with two subcutaneous doses of autologous monocyte-derived DCs pulsed with autologous tumor lysates and IL-2 to evaluate the safety and feasibility of this therapeutic strategy and characterize the antigen-specific immune alterations induced by this treatment. Here, IL2 is linked to neoplasm.